X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1616) 1616
life sciences & biomedicine (1568) 1568
humans (1523) 1523
male (997) 997
animals (922) 922
female (695) 695
cardiovascular system & cardiology (616) 616
ticlopidine - analogs & derivatives (568) 568
purinergic p2y receptor antagonists - administration & dosage (537) 537
middle aged (492) 492
cardiac & cardiovascular systems (475) 475
platelet aggregation inhibitors - administration & dosage (450) 450
purinergic p2y receptor antagonists - therapeutic use (445) 445
aged (438) 438
adenosine - analogs & derivatives (437) 437
treatment outcome (402) 402
platelet aggregation inhibitors - therapeutic use (399) 399
clopidogrel (386) 386
purinergic p2y receptor antagonists - adverse effects (356) 356
platelet aggregation inhibitors - adverse effects (331) 331
rats (331) 331
pharmacology & pharmacy (318) 318
ticagrelor (310) 310
neurosciences (301) 301
platelet aggregation - drug effects (286) 286
blood platelets - drug effects (285) 285
neurosciences & neurology (281) 281
mice (270) 270
ticlopidine - administration & dosage (268) 268
dose-response relationship, drug (258) 258
ticlopidine - therapeutic use (258) 258
acute coronary syndrome - drug therapy (256) 256
abridged index medicus (252) 252
time factors (247) 247
prasugrel hydrochloride (245) 245
atp (244) 244
purinergic p2y receptor antagonists - pharmacology (243) 243
purinergic p2 receptor antagonists (230) 230
prasugrel (225) 225
receptors, purinergic p2 - metabolism (219) 219
platelet aggregation inhibitors - pharmacology (218) 218
peripheral vascular disease (217) 217
adenosine - administration & dosage (216) 216
risk factors (212) 212
percutaneous coronary intervention (209) 209
hematology (207) 207
adenosine triphosphate - pharmacology (205) 205
acute coronary syndromes (195) 195
drug therapy, combination (192) 192
cardiovascular (190) 190
hemorrhage - chemically induced (188) 188
blood platelets - metabolism (187) 187
adenosine - therapeutic use (184) 184
adenosine triphosphate - metabolism (180) 180
rats, sprague-dawley (180) 180
adult (179) 179
platelet function tests (177) 177
prospective studies (177) 177
ticlopidine - adverse effects (172) 172
analysis (171) 171
adenosine (170) 170
aspirin (168) 168
blood platelets (162) 162
cell biology (162) 162
coronary heart disease (161) 161
heart attacks (161) 161
physiology (158) 158
cardiac patients (157) 157
care and treatment (156) 156
cardiology (153) 153
acute coronary syndrome (150) 150
aspirin - therapeutic use (148) 148
thrombosis (147) 147
aspirin - administration & dosage (146) 146
biochemistry & molecular biology (145) 145
drug therapy (144) 144
p2y (144) 144
signal transduction (140) 140
adenosine - adverse effects (138) 138
administration, oral (137) 137
ticlopidine - pharmacology (136) 136
adenosine triphosphate - analogs & derivatives (135) 135
research (131) 131
biomedicine (130) 130
stents (129) 129
disease models, animal (126) 126
platelets (125) 125
purinergic p2y receptor antagonists - pharmacokinetics (124) 124
platelet activation - drug effects (123) 123
adenosine monophosphate - analogs & derivatives (122) 122
receptors, purinergic p2 - physiology (122) 122
myocardial infarction (121) 121
receptors, purinergic p2y12 - drug effects (121) 121
inflammation (120) 120
thiophenes - administration & dosage (119) 119
piperazines - administration & dosage (118) 118
cells, cultured (117) 117
percutaneous coronary intervention - adverse effects (117) 117
adenosine - pharmacology (116) 116
medicine & public health (116) 116
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2186) 2186
German (12) 12
Italian (8) 8
French (6) 6
Russian (5) 5
Chinese (2) 2
Japanese (2) 2
Danish (1) 1
Hungarian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 12/2016, Volume 375, Issue 25, pp. 2423 - 2434
... – 3 Dual antiplatelet therapy (DAPT) with a P2Y 12 inhibitor and aspirin is superior to oral anticoagulation with a vitamin K antagonist in reducing the risk of thrombosis in patients undergoing placement of a first-generation stent, 4... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Confidence Intervals | Humans | Middle Aged | Male | Hemorrhage - prevention & control | Rivaroxaban - administration & dosage | Factor Xa Inhibitors - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Vitamin K - antagonists & inhibitors | Rivaroxaban - adverse effects | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Kaplan-Meier Estimate | Factor Xa Inhibitors - adverse effects | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Prevention | Complications and side effects | Angiography | Atrial fibrillation | Hemorrhage | Patients | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Angioplasty | Coagulation | Thrombosis | Thrombolysis | Bleeding | Fibrillation | Implants | Vitamin K | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 09/2014, Volume 371, Issue 11, pp. 1016 - 1027
.... Effective antiplatelet therapy combining the inhibition of both thromboxane A 2 –dependent platelet aggregation and P2Y 12 receptors is necessary in patients undergoing percutaneous coronary intervention (PCI... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - mortality | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Drug Therapy, Combination | Myocardial Infarction - diagnosis | Double-Blind Method | Time-to-Treatment | Anticoagulants - therapeutic use | Electrocardiography - drug effects | Adenosine - administration & dosage | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Coronary Angiography | Myocardial Infarction - drug therapy | Myocardial Reperfusion | Adenosine - analogs & derivatives | Aged | Hemorrhage - chemically induced | Emergency Medical Services | Administration | Care and treatment | Hospitals | Research | Management | Heart attack | Risk factors | Myocardial infarction | Heart attacks | Catheterization | Angiography | Clinical trials | Patients | Thrombosis | Thrombolysis | Bleeding | Clinical outcomes | Studies | Reperfusion | Blood platelets | Coronary vessels | Implants | Intubation | Acute coronary syndromes | Drug therapy | Index Medicus | Abridged Index Medicus | Infart de miocardi | Adenosine | Malalties coronàries | Anticoagulants (Medicine) | Anticoagulants (Medicina) | Adenosina | Coronary diseases
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial fibrillation... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 07/2016, Volume 375, Issue 1, pp. 35 - 43
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 12/2010, Volume 122, Issue 24, pp. 2619 - 2633
proton pump inhibitors | antiplatelet drugs | gastrointestinal hemorrhage | platelet aggregation inhibitors | aspirin | thienopyridine | AHA Scientific Statements | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
... established. We investigated the efficacy and safety of ticagrelor, a P2Y(12) receptor antagonist with established efficacy after an acute coronary syndrome, in this context... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 12/2010, Volume 105, Issue 12, pp. 2533 - 2549
This expert consensus document was developed by the American College of Cardiology Foundation (ACCF), the American College of Gastroenterology (ACG), and the... 
proton pump inhibitors | aspirin | ACCF Expert Consensus Document antiplatelet drugs | gastrointestinal hemorrhage | thienopyridine | platelet aggregation inhibitors | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Piperazines - administration & dosage | Prasugrel Hydrochloride | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Cardiovascular Diseases - drug therapy | Humans | Thienopyridines - adverse effects | Thienopyridines - metabolism | Piperazines - metabolism | Thiophenes - metabolism | Thiophenes - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - metabolism | Histamine H2 Antagonists - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Aspirin - adverse effects | Aspirin - metabolism | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - metabolism | Ticlopidine - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - metabolism | Platelet Aggregation Inhibitors - metabolism | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Thienopyridines - administration & dosage | Risk Factors | Histamine H2 Antagonists - adverse effects | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Aryl Hydrocarbon Hydroxylases - metabolism | Gastrointestinal Hemorrhage - chemically induced | Gastrointestinal Hemorrhage - prevention & control | Histamine H2 Antagonists - metabolism | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Cytochrome P-450 CYP2C19 | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Proton Pump Inhibitors - metabolism
Journal Article